| Name | Title | Contact Details |
|---|
BDO is a leading professional services organisation and are global leaders of the mid-tier. Operating in over 166 countries, our team of over 115,600 multi-functional experts work to provide business advice, that is driven by practical experience and up-to-date knowledge. With an objective of delivering an exceptional experience to each of our clients, we are continuously embracing newer technologies and approaches to deliver solutions that are best suited to address current business needs, as much as being future-ready. We are proud to be a people-powered business that focuses on deriving value through innovation and strong people relations. BDO India, is a key member of the global BDO organisation, employing over 9500 professionals across 18 offices in 12 key cities - Ahmedabad, Bengaluru, Chandigarh, Chennai, Coimbatore, Delhi NCR, Goa, Hyderabad, Kochi, Kolkata, Mumbai and Pune. We offer Assurance, Tax, Advisory, Business Services & Outsourcing, and Digital Services to both domestic and international clients across a range of industries. With an inherent culture of putting people first, we demonstrate our true purpose of being an organisation of People Helping People.
Continental Generals mission is to assist our customers with managing the financial risks and challenges that come as they age. Our skills, resources, and infrastructure allow us to help them with insulating and enhancing retirement income and maneuvering caregiving options. Thus allowing us to responsibly be a part of the solution rather than the problem. Our team of long-term care industry experts, with headquarters in Austin, Texas, strives to build value through superior operating results. As we manage our current portfolio of business, we continue to pursue growth opportunities for expansion and economies of scale through strategic acquisitions, mergers, and reinsurance opportunities. Our family of insurance companies and strategic partners provide administrative services to approximately 125,000 Long-Term Care, Life, Annuity and Supplemental Health customers. We are dedicated to upholding the commitments we have made to provide excellent service to all our customers and serve the needs of our claimants and their families during difficult times.
Fleetworx help the car fleet supply chain work better for everyone. We do this by combining data analytics with technology and expertise. Our specialist services help businesses deliver robust company car fleet management in the UK and across EMEA. We leverage data analytics to dramatically improve decision making and our expertise and practical influence spans the entire fleet supply chain. Our primary objective is to deliver savings, compliance and control and our focused and impartial approach is proven to deliver a significant return on investment. Savings - we provide client-side support in the design and delivery of cost-saving and carbon-saving company car policies. Compliance - we act as an extension of your business. Our robust Management Information System, Fleetworx Centrax, ensure you and your supply chain is fully compliant. Control - we impose tight control on all aspects of your company car fleet, creating a slick, cost-effective and valued reward and retention solution. Our services are particularly valued by fleet generalists in HR/procurement or finance roles who have company car fleet responsibility Contact us at sales@fleetworx.com or visit our website to read our thoughts on the fleet sector and learn more about how we help our clients.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.